Autoantibodies targeting both AIMP2-DX2 and AIMP2 have been detected in human serum, with an elevated AIMP2-DX2 to AIMP2 ratio correlating with poorer clinical outcomes in lung cancer patients. Here, AIMP2 is linked to lung carcinoma.